Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer Valabrega G; Montemurro F; Aglietta MAnn Oncol 2007[Jun]; 18 (6): 977-84Trastuzumab is a humanized mAb directed against the extracellular domain of the tyrosine kinase receptor HER2. Trastuzumab has shown clinical activity in HER2-overexpressing breast cancers and, at present, is currently approved for patients whose tumours have this abnormality, in both the metastatic and the adjuvant setting. Several issues about its optimal use, however, are still unresolved. One of the reasons for these uncertainties lies in the absence of conclusive data about its mechanism of action and possible primary or acquired resistance mechanisms. Therefore, clinical questions such as how to optimize patient selection, how to prevent resistance to trastuzumab, or what is the optimal management of those patients whose tumours progress during treatment still await convincing answers. This review summarises the current knowledge on the preclinical and clinical evidence about the mechanism of action of trastuzumab and on the mechanisms underlying the development of resistance and also briefly discusses their possible clinical implications.|*Drug Resistance, Neoplasm[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/*therapeutic use[MESH]|Antineoplastic Agents/*therapeutic use[MESH]|Breast Neoplasms/blood supply/*drug therapy/*genetics[MESH]|Female[MESH]|Gefitinib[MESH]|Gene Expression Regulation, Neoplastic[MESH]|Genes, erbB-2[MESH]|Humans[MESH]|Lapatinib[MESH]|Neovascularization, Pathologic/prevention & control[MESH]|Phosphatidylinositol 3-Kinases/metabolism[MESH]|Phosphoinositide-3 Kinase Inhibitors[MESH]|Quinazolines/therapeutic use[MESH]|Receptor, ErbB-2/*genetics[MESH]|Trastuzumab[MESH] |